Hinz Stefan
Aktuelle Urol. 2017 May;48(3):225-229. doi: 10.1055/s-0042-117570. Epub 2017 Jun 14.
Treatments currently available for metastatic castration-resistant prostate cancer (mCRPC) include abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, and radium-223. However, the optimal sequence of these agents is still unclear, and markers to predict treatment response and facilitate patient selection remain an unmet need. In terms of overall survival, it is crucial that patients receive all treatment options currently available. This requires early detection of progression as an indication for a treatment switch. In this context, a structured monitoring of treatment is important in clinical practice.
目前可用于转移性去势抵抗性前列腺癌（mCRPC）的治疗方法包括醋酸阿比特龙、恩杂鲁胺、多西他赛、卡巴他赛和镭-223。然而，这些药物的最佳使用顺序仍不明确，预测治疗反应并有助于患者选择的标志物仍是尚未满足的需求。就总生存期而言，患者接受目前所有可用的治疗选择至关重要。这需要早期检测疾病进展，作为治疗转换的指征。在此背景下，在临床实践中对治疗进行结构化监测很重要。
